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the quantitative scoring method, and 
the biological replicates that were per-
formed. The current sensitivity of mass 
spectrometry, combined with available 
protein databases, makes protein iden-
tification accurate and efficient such that 
even weaker interactions can be identi-
fied. The approach taken by Sowa et al. 
to find high-confidence interaction pro-
teins of DUBs from mass spectrometry 
data is systematic and unbiased. Thus, 
it is highly valuable to those seeking to 
identify and analyze protein interactions 
by mass spectrometry. Although such 
efforts are in many cases accurate in 
delineating interactions, they remain in 
great need of a CompPASS to under-
stand where the findings lie on the bio-
logical map. The greatest value of the 
approach taken by Sowa et al. may be 
in the ability to link a protein of interest 
to a defined biological pathway, thereby 
allowing for more focused hypotheses 
and experiments.
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In this issue, Sabin et al. (2009) and Gruber et al. (2009) reveal the protein Ars2 as a versatile 
regulator of RNA silencing. They show that Ars2 stimulates microRNA processing, contributes to 
antiviral resistance in flies, and is important for cell proliferation in mammals.MicroRNAs (miRNAs) are 21–23 nt 
RNAs that interact with Argonaute (Ago) 
proteins to regulate gene expression 
in plants and animals through cleav-
age or translational repression of tar-
get mRNAs (Carthew and Sontheimer, 
2009). In animals, the processing steps 
required to transform initial primary 
miRNA transcripts (pri-miRNAs) to 
mature miRNAs are carried out by the 
RNase III enzymes Drosha (assisted by 
the RNA-binding protein DGCR8/Pasha 
in a complex known as the Micropro-
cessor) and Dicer (Kim et al., 2009) 
(Figure 1). Although RNA silencing in 
vertebrates is centered on endogenous 
RNAs, flies, worms, and plants utilize 
the small-interfering RNA (siRNA) path-
way to fight viral infection by using viral 
double-stranded RNA as a template for 
the synthesis of small effector RNAs 
(Ding and Voinnet, 2007). Two parallel 224 Cell 138, July 24, 2009 ©2009 Elsevier IRNA silencing pathways exist in Droso-
phila with Dicer-1 and Ago1 supporting 
the miRNA pathway, and Dicer-2, Ago2, 
and the RNA-binding protein R2D2 
supporting the siRNA pathway (Figure 
1) (Carthew and Sontheimer, 2009). The 
findings reported by the Cherry and 
Thompson labs in this issue identify 
Ars2 as a new factor in the RNA silenc-
ing machinery that functions in antiviral 
defense in flies (Sabin et al., 2009) and 
cell proliferation in mammals (Gruber 
et al., 2009).
Mammalian cellular proliferation and 
intrinsic antiviral defense in Drosophila 
are seemingly unrelated processes, 
and it therefore comes as a surprise 
that a single protein factor is at the 
core of both mechanisms. In mam-
mals, a truncated version of Ars2 has 
been implicated in arsenic resistance, 
but the full-length protein regulates cell nc.proliferation through a possible effect 
on RNA metabolism (Wilson et al., 
2008). Interestingly, the plant homolog 
of Ars2, SERRATE, is an essential fac-
tor in miRNA biogenesis (Grigg et al., 
2005) that interacts with the nuclear 
cap-binding complex (CBC) (Laubinger 
et al., 2008) and the RNase III enzyme 
Dicer-Like 1 (DCL1) (Dong et al., 2008).
In a search for factors mediating viral 
resistance in Drosophila, the Cherry 
lab performed a small-scale screen 
and found that loss of Ars2 results in a 
5-fold increase in infectivity for several 
RNA viruses in both cell culture and 
adult flies (Sabin et al., 2009). Given 
that viral infection is counteracted 
by siRNAs in Drosophila, the authors 
sought a connection between these 
two pathways. They observe a dramatic 
relief of siRNA-mediated silencing 
upon Ars2 knockdown and show that 
figure 1. Ars2 Is Implicated at Multiple steps in the Biogenesis of small RnAs
(A) Ars2 and the cap-binding complex (CBC) may recruit the Microprocessor to nascent primary micro-
RNA (pri-miRNA) transcripts. 
(B) Ars2 may also play a more general role in pre-mRNA splicing. 
(C) Ars2 could stimulate RNase III cleavage activity and fidelity, possibly with a direct contribution from 
the CBC. Although the figure depicts the RNA silencing pathways in the fruit fly Drosophila, the processes 
are identical in other animals apart from the separation of miRNA and small-interfering RNA (siRNA) path-
ways at the level of Dicer. Some steps and factors are omitted for clarity.Ars2 directly interacts with Dicer-2 and 
facilitates the production of siRNAs in 
the cytoplasm. In addition, Ars2 knock-
down impairs miRNA-mediated silenc-
ing and reduces pri-miRNA transcript 
levels, suggesting a role for Ars2 in sta-
bilizing pri-miRNAs. The plant homolog 
of Ars2, SERRATE, interacts with the 
CBC (Laubinger et al., 2008), and con-
versely a knockout of the CBC compo-
nents CBP20 and CBP80 in Drosophila 
results in increased viral infectivity and 
loss of RNA silencing. Surprisingly, 
none of the well-known components of 
the RNA silencing machinery (Dicer-2, 
Ago2, R2D2) show up as regulators of 
viral infectivity in the screen; however, 
this could be explained by the relatively 
small number of genes tested (about 
100).
Working in mammalian cells, the 
Thompson lab investigated the mecha-
nism behind Ars2-mediated cell survival 
and find that the loss of Ars2 causes 
severe proliferation defects in condi-tional knockout mice and in mouse and 
human cell lines deficient in Ars2. Mass 
spectrometry analysis shows that Ars2 
associates with the CBC component 
CBP80, but not with its cytoplasmic 
counterpart eIF4E, and interacts specif-
ically with capped RNAs. This suggests 
a functional overlap with SERRATE: 
both Ars2 and the CBC are required for 
miRNA- mediated silencing, and Ars2 
furthermore binds Drosha and stimu-
lates cleavage activity and fidelity for a 
subset of pri- miRNAs. Importantly, Ars2 
expression is low during cell quiescence 
and high during proliferation, suggest-
ing that correct pri-miRNA processing 
may be correlated with the proliferative 
state of the cell.
The authors suggest two nonexclu-
sive models to explain the many roles 
of Ars2 in RNA silencing in flies and 
mammals (Figure 1). In the first model, 
a complex of CBC and Ars2 recruits the 
Microprocessor to nascent pri-miRNA 
transcripts as seen for SERRATE in Cellplants (Figure 1A); pri-miRNA process-
ing has been shown to occur cotran-
scriptionally, even preceding splicing 
(Morlando et al., 2008), and the efficient 
recruitment of the Micro processor is 
therefore essential. Ars2 may simul-
taneously stabilize pri-miRNA tran-
scripts, although the opposite is seen 
for SERRATE in plants (Laubinger et 
al., 2008). The second model suggests 
that Ars2 enhances the cleavage activ-
ity and possibly the specificity of RNase 
III enzymes (Figure 1C); although this 
model would explain the widespread 
function of Ars2 in RNA silencing and is 
supported by studies in plants, it should 
be investigated further in a recombinant 
system, similar to prior investigation of 
DCL1 and SERRATE (Dong et al., 2008). 
Neither of the models explain why only 
some miRNAs are dependent on Ars2 
and the CBC for their expression, but it 
is tempting to speculate that genomic 
location (intronic or intergenic tran-
scripts) or RNA secondary structure will 
determine if accessory processing fac-
tors are required.
The exact role of Ars2 and the CBC 
in antiviral defense in Drosophila war-
rants further investigation. Given that 
the CBC is expected to affect process-
ing of mRNAs as well as miRNAs it will 
be crucial to distinguish between a spe-
cific role in battling viral infection and a 
more general effect on mRNA process-
ing. In plants, SERRATE and the CBC 
play dual roles in stimulating splicing 
as well as miRNA processing (Laub-
inger et al., 2008), and future studies 
should address whether Ars2 serves 
similar functions in both miRNA and 
mRNA processing in animals (Figure 
1B). The existence of an RNAi-based 
antiviral system in vertebrates is con-
troversial, but it would still be interest-
ing to see if knockdown of Ars2 affects 
viral infectivity in mammalian cells.
The two studies described here shed 
light on an evolutionarily conserved link 
between the RNA silencing pathway 
and mRNA processing but leave several 
questions open: Is the Microprocessor 
recruited to all capped, nascent tran-
scripts or does an additional specificity 
factor distinguish between pri-miRNAs 
and pre-mRNAs? Can Ars2 directly bind 
to miRNA precursors as seen for other 
proteins modulating pri-miRNA process- 138, July 24, 2009 ©2009 Elsevier Inc. 225
ing or is it only engaged in protein-protein 
interactions? Is the increase in Ars2 lev-
els observed during the transition from 
cell quiescence to proliferation reflected 
in expression of miRNAs dependent on 
Ars2 for correct processing? And if so, 
what sequence or structure motif causes 
these miRNAs to be responsive to Ars2? 
Finally, given the small number of genes 
screened for involvement in viral resis-
tance, how many other regulatory com-
ponents are still waiting to be identified? 
With a growing understanding of the 
mechanisms behind small RNA path-
ways the new challenge in RNA biology is 
to understand how the silencing machin-226 Cell 138, July 24, 2009 ©2009 Elsevier 
The cancer stem cell hypothesis postu-
lates that the progeny of a small pluripo-
tent population of malignant stem cells 
makes up the bulk of a malignant tumor. 
Among cancers, acute myeloid leukemia 
(AML) has the most clearly defined popu-
lation of stem cells—known as leukemic 
stem cells (LSCs)—that is responsible for 
AML persistence and relapse. Therefore, 
there is considerable interest in identify-
ing therapies that specifically target this 
particular population of cells. Leukemic 
stem cells and their normal counterpart, 
the hematopoietic stem cells (HSCs), 
show remarkable resilience to the direct 
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metabolism. We have certainly not seen 
the last canonical RNA metabolic factor 
crossing over into the miRNA field.
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cytotoxic and indirect inflammatory 
effects of chemotherapy. This results, in 
part, from their ability to circulate freely 
in the peripheral blood and repopulate 
the bone marrow stem cell niche while 
avoiding phagocytosis by activated 
macrophages (Figure 1). In this issue of 
Cell, Jaiswal et al. (2009) and Majeti et al. 
(2009) show that the immunoglobulin-like 
protein CD47 expressed by LSCs acts as 
an inhibitor of macrophage activity and 
directly promotes enhanced survival and 
engraftment of LSCs (Figure 1). Further-
more, they demonstrate that high levels 
of CD47 on LSCs isolated from patients 
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1503–1514.with AML are predictive of leukemia 
resistance to therapy, possibly reflecting 
the ability of LSCs to avoid macrophage-
mediated control.
CD47 is a membrane protein that 
functions in neutrophil trafficking, T cell 
costimulation, and neuronal regenera-
tion (Matozaki et al., 2009). CD47 also 
interacts with a specific macrophage 
receptor, SIRPα, to downregulate the 
phagocytic potential of macrophages 
(van den Berg and van der Schoot, 
2008). Given that mobilized HSCs in the 
blood stream come into contact with 
macrophages of the reticulo-endothelial 
eukemia 
 cells to avoid phagocytosis by 
(2009) show that elevated CD47 
nd is an indicator of poor prog-
